Investors
A differentiated, asset-backed CRO with proprietary IP
An aligned-incentive business model, owned facilities, proprietary technology, and 15 years of organic growth across 29 countries.
Why CEBIS is a distinctive asset
CEBIS combines strengths most CROs lack — a shared-risk commercial model that aligns incentives with sponsors, proprietary Trial-HUB® technology, owned preclinical and Phase I facilities, and a dual revenue engine spanning Clinical & Regulatory Services and recurring Patient Support Programs. Growth has been entirely organic across 29 countries and three continents, and CEBIS has been recognized as a Top-10 biopharmaceutical service company in Europe.
The investment thesis
- Proprietary IP — Trial-HUB®, an in-house platform with measurable efficiency gains (~20% faster setup, 25% resource efficiency, 30% IT savings).
- Aligned, defensible model — shared-risk and milestone-based pricing, including clinical-development co-investment.
- Dual revenue engine — clinical research plus recurring patient-support programs (55,000+ patients supported).
- Asset-backed — owned preclinical GLP facility and a Phase I clinical-pharmacology unit.
- Organic growth track record — 15 years, 29 countries, three continents, built without acquisitions.
For qualified investors, we can provide a confidential briefing on the model, the technology IP and the growth roadmap.